San Antonio—Should clinicians routinely use carboplatin in the neoadjuvant setting for triple-negative breast cancer (TNBC), and is pathologic complete response (pCR) a clinically meaningful surrogate outcome in TNBC? Results from two randomized trials, GeparSixto and CALGB 40603, presented at the 2015 San Antonio Breast Cancer Symposium (SABCS; abstracts S2-04 and S2-05) provided conflicting answers to these questions.
Gunter von Minckwitz, MD, the chairman of the German Breast Group